X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-08-12 | CUE | Cue Biopharma, Inc. | Lin Shao-Lee | CEO | S - Sale+OE | $27.58 | -58,258 | 705,995 | -8% | -$1,606,562 | |||||
| D | 2026-08-12 | IRON | Disc Medicine, Inc. | Yu Jonathan Yen-Wen | COO | S - Sale+OE | $82.64 | -804 | 54,324 | -1% | -$66,445 | |||||
| D | 2026-08-13 | RYTM | Rhythm Pharmaceuticals, Inc. | Lee Jennifer Kayden | EVP, Head of North America | S - Sale+OE | $117.38 | -75,834 | 0 | -100% | -$8,901,531 | |||||
| D | 2026-08-12 | RYTM | Rhythm Pharmaceuticals, Inc. | Mazabraud Yann | EVP, Head of International | S - Sale+OE | $116.15 | -57,000 | 55,655 | -51% | -$6,620,575 | |||||
2026-08-12 | MANE | Veradermics, Inc | Childs John W | Dir | S - Sale | $107.12 | -100,000 | 2,102,006 | -5% | -$10,711,700 | ||||||
| D | 2026-08-14 | ORKA | Oruka Therapeutics, Inc. | Quinlan Paul T | GC | S - Sale+OE | $108.49 | -52,000 | 31,034 | -63% | -$5,641,409 | |||||
2026-08-12 | SEPN | Septerna, Inc. | Third Rock Ventures V, L.P. | 10% | S - Sale | $50.27 | -147,200 | 10,280,050 | -1% | -$7,399,858 | ||||||
| D | 2026-08-13 | ORKA | Oruka Therapeutics, Inc. | Agarwal Arjun | SVP, Finance | S - Sale+OE | $106.66 | -10,000 | 15,312 | -40% | -$1,066,572 | |||||
2026-08-14 | CTTH | Ctt Pharmaceutical Holdings, Inc. | Ctt Pharmaceutical Holdings, Inc. | CEO | P - Purchase | $0.06 | +1,800 | 9,355,456 | 0% | +$112 | ||||||
2026-08-12 | SEPN | Septerna, Inc. | Ra Capital Management, L.P. | Dir, 10% | S - Sale | $42.50 | -1,493,000 | 725,443 | -67% | -$63,452,500 | ||||||
| D | 2026-08-12 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $292.07 | -31,641 | 27,696 | -53% | -$9,241,229 | |||||
| D | 2026-08-12 | LGND | Ligand Pharmaceuticals Inc | Haas Jason | Dir | S - Sale+OE | $292.81 | -7,138 | 3,981 | -64% | -$2,090,062 | |||||
| DM | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Donovan Joanne M. | CMO | S - Sale+OE | $43.71 | -9,441 | 8,625 | -52% | -$412,703 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Russell Alan J | Chief Scientific Officer | S - Sale+OE | $43.73 | -5,901 | 31,466 | -16% | -$258,042 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Moore John R | GC | S - Sale+OE | $43.82 | -5,016 | 17,697 | -22% | -$219,823 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Derakhshan Behrad | Chief Business Officer | S - Sale+OE | $43.81 | -5,100 | 31,826 | -14% | -$223,424 | |||||
| D | 2026-08-12 | EWTX | Edgewise Therapeutics, Inc. | Koch Kevin | Pres, CEO | S - Sale+OE | $43.68 | -17,971 | 52,488 | -26% | -$785,042 | |||||
| D | 2026-08-13 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $504.24 | -9,500 | 668,728 | -1% | -$4,790,316 | |||||
| D | 2026-08-13 | JNJ | Johnson & Johnson | Duato Joaquin | CEO, COB | S - Sale+OE | $261.17 | -123,291 | 307,837 | -29% | -$32,199,927 | |||||
2026-08-13 | AMRX | Amneal Pharmaceuticals, Inc. | Kiely John | Dir | S - Sale | $17.64 | -50,000 | 200,252 | -20% | -$882,000 | ||||||
2026-08-12 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $71.50 | +951 | 509,887 | 0% | +$67,997 | ||||||
2026-08-14 | ABCL | Abcellera Biologics Inc. | Booth Andrew | CFO | P - Purchase | $10.32 | +37,200 | 613,759 | +6% | +$383,904 | ||||||
2026-08-12 | ABCL | Abcellera Biologics Inc. | Hayden Michael R | Dir | P - Purchase | $10.37 | +46,387 | 1,438,029 | +3% | +$481,033 | ||||||
2026-08-12 | BLTE | Belite Bio, Inc | Chuang Hao-Yuan | CFO | S - Sale | $180.35 | -367 | 93,433 | 0% | -$66,187 | ||||||
2026-08-12 | BLTE | Belite Bio, Inc | Lin Yu-Hsin | CEO | S - Sale | $180.35 | -365 | 170,569 | 0% | -$65,827 | ||||||
| D | 2026-08-11 | WVE | Wave Life Sciences, Inc. | Wagner Heidi L | Dir | S - Sale+OE | $6.01 | -7,000 | 44,930 | -13% | -$42,070 | |||||
2026-08-12 | WVE | Wave Life Sciences, Inc. | Rawcliffe Adrian | Dir | S - Sale | $5.29 | -12,700 | 0 | -100% | -$67,183 | ||||||
2026-08-11 | WVE | Wave Life Sciences, Inc. | Takanashi Ken | Dir | S - Sale | $6.01 | -3,864 | 9,626,487 | 0% | -$23,223 | ||||||
2026-08-11 | WVE | Wave Life Sciences, Inc. | Tan Aik Na | Dir | S - Sale | $6.01 | -432 | 24,968 | -2% | -$2,596 | ||||||
| D | 2026-08-11 | ONC | Beone Medicines Ltd. | Lee Chan Henry | SVP, GC | S - Sale+OE | $360.00 | -2,666 | 325,312 | -1% | -$959,760 | |||||
| DM | 2026-08-11 | ARQT | Arcutis Biotherapeutics, Inc. | Burnett Patrick | See Remarks | S - Sale+OE | $26.33 | -15,000 | 119,289 | -11% | -$394,897 | |||||
| D | 2026-08-11 | SEPN | Septerna, Inc. | Bhatt Elizabeth | Pres, COO | S - Sale+OE | $44.00 | -25,000 | 174,209 | -13% | -$1,100,000 | |||||
2026-08-11 | ABT | Abbott Laboratories | Morrone Louis H. | EVP | S - Sale | $109.83 | -5,850 | 70,724 | -8% | -$642,506 | ||||||
| D | 2026-08-12 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $515.03 | -9,500 | 668,728 | -1% | -$4,892,748 | |||||
2026-08-11 | KRRO | Korro Bio, Inc. | Formela Jean Francois | Dir | S - Sale | $13.96 | -2,143 | 145,937 | -1% | -$29,916 | ||||||
2026-08-13 | MRK | Merck & Co., Inc. | Guindo Chirfi | EVP, Access, Policy, Comms | S - Sale | $135.00 | -10,000 | 36,613 | -21% | -$1,350,000 | ||||||
2026-08-11 | XENE | Xenon Pharmaceuticals Inc. | Gannon Steven | Dir | S - Sale | $64.06 | -10,000 | 1,870 | -84% | -$640,550 | ||||||
2026-08-13 | ANIP | Ani Pharmaceuticals Inc | Cook Meredith | SVP, GC, SEC. | S - Sale | $75.48 | -500 | 74,424 | -1% | -$37,740 | ||||||
2026-08-12 | ELAN | Elanco Animal Health Inc | Harrington Michael J | Dir | P - Purchase | $21.82 | +5,000 | 131,451 | +4% | +$109,100 | ||||||
2026-08-12 | AMRX | Amneal Pharmaceuticals, Inc. | Shah Nikita | EVP | S - Sale | $17.51 | -146,403 | 253,390 | -37% | -$2,563,517 | ||||||
| M | 2026-08-11 | AMRX | Amneal Pharmaceuticals, Inc. | Daly Jason B. | EVP, GC | S - Sale | $17.41 | -216,613 | 35,171 | -86% | -$3,771,050 | |||||
2026-08-12 | ZLAB | Zai Lab Ltd | Lis William | Dir | S - Sale | $25.00 | -8,506 | 41,931 | -17% | -$212,650 | ||||||
2026-08-11 | RCKT | Rocket Pharmaceuticals, Inc. | Stevens Christopher James | COO | S - Sale | $3.50 | -36,658 | 505,784 | -7% | -$128,266 | ||||||
2026-08-11 | RCKT | Rocket Pharmaceuticals, Inc. | Chaudhuri Sarbani | See Remarks | S - Sale | $3.50 | -4,701 | 262,809 | -2% | -$16,449 | ||||||
2026-08-11 | ZLAB | Zai Lab Ltd | Chen Yajing | CFO | S - Sale | $25.00 | -619 | 35,072 | -2% | -$15,475 | ||||||
| D | 2026-08-12 | MRK | Merck & Co., Inc. | Zachary Jennifer | EVP, GC | S - Sale+OE | $133.46 | -80,315 | 45,509 | -64% | -$10,718,495 | |||||
2026-08-13 | ALT | Altimmune, Inc. | Durso Jerome Benedict | Pres, CEO | P - Purchase | $2.95 | +15,000 | 62,500 | +32% | +$44,250 | ||||||
| M | 2026-08-06 | KRRO | Korro Bio, Inc. | Lynx1 Capital Management LP | 10% | P - Purchase | $11.79 | +6,684 | 1,544,980 | 0% | +$78,809 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Farajallah Awny Samaan Botros | Chief Medical Officer | S - Sale | $17.10 | -14,006 | 116,177 | -11% | -$239,503 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Ibrahim Ramy Riad Ahmed | Pres, PDT BU | S - Sale | $17.10 | -7,277 | 102,588 | -7% | -$124,437 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Pacheco Rhonda Janice | Pres, U.S. Business Unit | S - Sale | $17.10 | -16,901 | 182,507 | -8% | -$289,007 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Duprey Lauren Rusckowski | Chief Transformation Officer | S - Sale | $17.10 | -47,586 | 226,057 | -17% | -$813,721 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Plump Andrew Stewart | Pres, R, D | S - Sale | $17.10 | -165,393 | 1,047,876 | -14% | -$2,828,220 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Pignagnoli Agosti Marcello | Head, Strat., Port. Dev | S - Sale | $17.10 | -22,957 | 176,977 | -11% | -$392,565 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Bitetti Teresa Marie | Pres, OBU | S - Sale | $17.10 | -50,012 | 252,010 | -17% | -$855,205 | ||||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Stetz Gary S. II | Dir | P - Purchase | $0.05 | +500,000 | 500,000 | New | +$25,000 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Shannon Elaine Mary | Pres, Global Supply, Quality | S - Sale | $17.10 | -3,978 | 63,333 | -6% | -$68,024 | ||||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Stetz Gary S. | Interim CEO | P - Purchase | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100,000 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Ricci Gabriele | Chief Data, Tech. Officer | S - Sale | $17.10 | -25,088 | 171,654 | -13% | -$429,005 | ||||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Purcell Michael J. | Dir | P - Purchase | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100,000 | |||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Appajosyula Sireesh | COO | P - Purchase | $0.05 | +2,000,000 | 3,250,000 | +160% | +$100,000 | |||||
| D | 2026-08-03 | HEPA | Hepion Pharmaceuticals, Inc. | Lopriore Vincent S | Exec COB | P - Purchase | $0.05 | +10,000,000 | 30,500,000 | +49% | +$500,000 | |||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Greenway Nicola Deidre Petal | CHRO | S - Sale | $17.10 | -6,774 | 53,029 | -11% | -$115,835 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Kim Julie So-Young | Pres, CEO | S - Sale | $17.10 | -89,090 | 391,489 | -19% | -$1,523,439 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Platford Giles Richard | Pres, IBU | S - Sale | $17.10 | -31,083 | 315,838 | -9% | -$531,519 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Furney Natalie Anne Marie | Global GC | S - Sale | $17.10 | -30,868 | 204,298 | -13% | -$527,843 | ||||||
| D | 2026-08-11 | SGMT | Sagimet Biosciences Inc. | Kemble George | Dir | S - Sale+OE | $9.95 | -20,206 | 62,161 | -25% | -$201,147 | |||||
| D | 2026-08-10 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $27.09 | -2,170 | 51,384 | -4% | -$58,785 | |||||
2026-08-11 | PTIX | Protagenic Therapeutics, Inc.New | Armen Garo H | EXEC. CHAIR, PRINCIPAL OFF | P - Purchase | $0.32 | +2,220 | 34,199 | +7% | +$710 | ||||||
| DM | 2026-08-10 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale+OE | $148.91 | -100,000 | 523,478 | -16% | -$14,890,799 | |||||
| AD | 2026-07-07 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $42.30 | -46,250 | 235,244 | -16% | -$1,956,187 | |||||
| AD | 2026-06-23 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $37.93 | -18,500 | 235,244 | -7% | -$701,769 | |||||
| AD | 2026-05-12 | VERA | Vera Therapeutics, Inc. | Fordyce Marshall | Pres, CEO | S - Sale+OE | $36.74 | -18,500 | 235,244 | -7% | -$679,747 | |||||
2026-08-11 | AMPH | Amphastar Pharmaceuticals, Inc. | Prins Richard K | Dir | S - Sale | $20.30 | -7,973 | 29,625 | -21% | -$161,852 | ||||||
| M | 2026-08-10 | ONC | Beone Medicines Ltd. | Oyler John | CEO | S - Sale | $359.12 | -240,810 | 47,362,982 | -1% | -$86,480,472 | |||||
| M | 2026-08-10 | IMNM | Immunome Inc. | Barchas Isaac | Dir | S - Sale | $26.35 | -83,464 | 92,211 | -48% | -$2,198,910 | |||||
2026-08-11 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale | $99.90 | -6,001 | 36,355 | -14% | -$599,510 | ||||||
| D | 2026-08-10 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $133.27 | -239,850 | 98,744 | -71% | -$31,964,810 | |||||
| D | 2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Gordon Carl L | Dir | P - Purchase | $16.00 | +625,000 | 2,714,279 | +30% | +$10,000,000 | |||||
2026-08-12 | XERS | Xeris Biopharma Holdings, Inc. | Pieper Steven | See Remarks | S - Sale | $8.50 | -5,000 | 1,361,053 | 0% | -$42,500 | ||||||
| D | 2026-08-10 | BLSM | Blossomhill Therapeutics, Inc. | Orbimed Advisors LLC | Dir | P - Purchase | $16.00 | +625,000 | 2,714,279 | +30% | +$10,000,000 | |||||
| M | 2026-08-10 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $47.25 | -51,499 | 588,566 | -8% | -$2,433,176 | |||||
| D | 2026-08-11 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $522.87 | -9,500 | 668,728 | -1% | -$4,967,292 | |||||
2026-08-11 | CRBP | Corbus Pharmaceuticals Holdings, Inc. | Saxena Nishant C | Chief Business Officer | P - Purchase | $9.63 | +2,600 | 77,900 | +3% | +$25,036 | ||||||
| D | 2026-08-10 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $114.52 | -1,031 | 119,472 | -1% | -$118,068 | |||||
| D | 2026-08-10 | CORT | Corcept Therapeutics Inc | Guyer William | Chief Development Officer | S - Sale+OE | $113.43 | -16,300 | 3,985 | -80% | -$1,848,890 | |||||
| D | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Hyep Ivan | CFO | S - Sale+OE | $27.97 | -12,500 | 129,855 | -9% | -$349,591 | |||||
| D | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | CEO | S - Sale+OE | $27.98 | -10,000 | 362,152 | -3% | -$279,750 | |||||
| D | 2026-08-10 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale+OE | $27.98 | -18,750 | 181,641 | -9% | -$524,533 | |||||
| D | 2026-08-10 | REGN | Regeneron Pharmaceuticals, Inc. | Guarini Kathryn | Dir | S - Sale+OE | $800.00 | -400 | 603 | -40% | -$320,000 | |||||
| D | 2026-08-10 | ZVRA | Zevra Therapeutics, Inc. | Watton Corey Michael | Dir | S - Sale+OE | $11.25 | -12,300 | 1,800 | -87% | -$138,377 | |||||
| D | 2026-08-10 | REGN | Regeneron Pharmaceuticals, Inc. | Zoghbi Huda Y | Dir | S - Sale+OE | $800.00 | -800 | 1,703 | -32% | -$640,000 | |||||
| M | 2026-08-10 | MRK | Merck & Co., Inc. | Deluca Richard R. | EVP, Pres, Merck Animal Heallt | S - Sale | $131.12 | -45,320 | 110,167 | -29% | -$5,942,369 | |||||
2026-08-11 | AVTX | Avalo Therapeutics, Inc. | Riley Jennifer | Chief Strategy Officer | S - Sale | $19.59 | -2,655 | 37,041 | -7% | -$52,012 | ||||||
| D | 2026-08-10 | AVTX | Avalo Therapeutics, Inc. | Doyle Mittie | Chief Medical Officer | S - Sale+OE | $20.00 | -679 | 51,776 | -1% | -$13,580 | |||||
2026-08-11 | TAK | Takeda Pharmaceutical Co Ltd | Shannon Elaine Mary | Pres, Global Supply, Quality | S - Sale | $17.55 | -20,363 | 67,311 | -23% | -$357,371 | ||||||
2026-08-10 | TAK | Takeda Pharmaceutical Co Ltd | Greenway Nicola Deidre Petal | CHRO | S - Sale | $17.51 | -34,603 | 59,803 | -37% | -$605,778 | ||||||
2026-08-12 | PFE | Pfizer Inc | Bourla Albert | COB, CEO | P - Purchase | $26.34 | +38,000 | 435,555 | +10% | +$1,000,920 | ||||||
2026-08-10 | NXTC | Nextcure, Inc. | Simcere Zaiming, Inc. | Former 10% Owner | S - Sale | $6.16 | -30,000 | 308,636 | -9% | -$184,800 | ||||||
2026-08-10 | ANIP | Ani Pharmaceuticals Inc | Gutwerg Ori | SVP, GENERICS | S - Sale | $77.00 | -3,162 | 75,534 | -4% | -$243,474 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |